Amario Snow Lima medical oncologist. I treat Melanoma and renal cell carcinoma. My major interest outside of these two diseases is really the development of immune therapies. I’ve been working on this probably for the past 35 years and it turns out that Melanoma and kidney cancer, which are the two diseases that are treated, are the most responsive to immune therapies, or at least there was a time when those were the only two diseases that were really responsive to immune therapies.
With these new drugs that we helped develop. Immunotherapy is now used in almost every kind of cancer, but initially it was Melanoma and kidney cancer and that’s why I was drawn to those two diseases and I’ve stayed with that for my entire career. We’re very satisfied that approximately 50% of the patients can be really treated effectively with the medicines that we have now, but the truth is, the other 50% don’t do well and can possibly die of their menist attic disease if not treated effectively.
Research is really important in finding more effective treatments for those other 50%. So our clinical research is really focused around finding new medications that can effectively treat those that don’t respond to the group of medications that work now, and we integrate our clinical research with our clinical practice. We feel that for the subset of patients that don’t have viable standard of care, alternative options we should be offering them the best available investigational therapies that are out there.
We take a very much a team approach to the treatment of our patients and we encourage people to ask questions and we try and spend as much time with them at the beginning. Of each patient journey at the very first visit to answer all the questions that they have. But the other thing that we try and do is we try and answer the questions that they may not know to ask, so as much as possible we try and have a very long conversation and I go through all aspects of the disease, Natural History, the treatment, and how we monitor for recurrence.
A number of visits.

I also introduce them to our practice nurses which are in really important part of our practice because those that’s the interface between the outside and. And into our clinic.